On the stock market since 2018, it operates in the world of health and science. It has 9,650 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
There is growth, but not at top-of-the-class tempo.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 31% below its peak. The market has trimmed its expectations for the company.
The company sells $4.7B a year; the problem isn’t sales — it’s costs running above that number.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 142 buys and 23 sells. Management buying with its own money is usually read as a good sign.
A loss of $232M against $4.7B in annual sales.
At the current pace of spending, the cash lasts about 2.3 years. After that, the company needs to find new money.
On our five-subject report card, ELAN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ELAN has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.